Our pipeline

Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
2022 Milestones
ONCOS-102 local delivery
PD1 Refractory Melanoma
Combination w/
anti PD1
4Q 2022 / 1Q 2023Initiation of phase 2 trial
ONCOS-102 local delivery
Mesothelioma
Combination w/pemetrexed/cisplatin
1H 2022Full study data at scientific conference
ONCOS-102 local delivery
Metastatic Colorectal cancer
Combination w/anti PDL1
1H 22Clinical data at scientific conference
Mutant KRAS immunotherapy
Multiple Myeloma
TG01 / QS-21
2H 2022
Initiation of clinical trial
circular RNA ONCOS vectors
-
2H 2022
Pre-clinical proof-of-concept data
Cancer Indication: PD1 Refractory Melanoma
Combination with: Combination w/
anti PD1
Product candidate: ONCOS-102 local delivery
Next expected event: 4Q 2022 / 1Q 2023 Initiation of phase 2 trial
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Mesothelioma
Combination with: Combination w/pemetrexed/cisplatin
Product candidate: ONCOS-102 local delivery
Next expected event: 1H 2022 Full study data at scientific conference
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Metastatic Colorectal cancer
Combination with: Combination w/anti PDL1
Product candidate: ONCOS-102 local delivery
Next expected event: 1H22 Clinical data at scientific conference
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Multiple Myeloma
Combination with: TG01 / QS-21
Product candidate: Mutant KRAS immunotherapy
Next expected event: 2H 2022
Initiation of clinical trial
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: -
Product candidate: circular RNA ONCOS vectors
Next expected event: 2H 2022
Pre-clinical proof-of-concept data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3